BioCentury | Feb 4, 2021
Management Tracks

Novo Foundation names Krogsgaard Thomsen CEO; plus Takeda’s Sequeira to become first woman to chair PhRMA and updates from Almirall, Twist, Oncosec and more

...was president and CEO of Spring Bank Pharmaceuticals Inc., which reverse-merged with F-star Therapeutics Inc. (NASDAQ:FSTX).Indapta Therapeutics Inc....
BioCentury | Jan 23, 2021
Emerging Company Profile

Technology showcase: BioCentury’s 2020 class of emerging companies

...Phase I testing to treat HER2-expressing solid tumors. Indapta Therapeutics Inc. is...
BioCentury | Sep 2, 2020
Management Tracks

Namouni to lead Blueprint R&D; plus Davar to head R&D at Acadia, Napolitano replaces Burow on Vir’s board, and more

...said it has started its first clinical trial, a Phase I study of cough candidate NOC-100.Indapta Therapeutics Inc....
...policy research organization’s CSO and EVP for the past 10 years. BC Staff Acadia Pharmaceuticals Inc. Nocion Therapeutics Inc. Indapta Therapeutics Inc. Blueprint...
BioCentury | Mar 14, 2020
Emerging Company Profile

Indapta harnesses natural NK cell subset to create allogeneic cancer therapy

...number of cancer patients it could treat relative to genetically edited allogeneic NK cell therapies. Indapta Therapeutics Inc....
...with undisclosed companies regarding partnerships that pair its G-NK cells with existing mAbs. COMPANY PROFILE Indapta Therapeutics Inc....
Items per page:
1 - 4 of 4
BioCentury | Feb 4, 2021
Management Tracks

Novo Foundation names Krogsgaard Thomsen CEO; plus Takeda’s Sequeira to become first woman to chair PhRMA and updates from Almirall, Twist, Oncosec and more

...was president and CEO of Spring Bank Pharmaceuticals Inc., which reverse-merged with F-star Therapeutics Inc. (NASDAQ:FSTX).Indapta Therapeutics Inc....
BioCentury | Jan 23, 2021
Emerging Company Profile

Technology showcase: BioCentury’s 2020 class of emerging companies

...Phase I testing to treat HER2-expressing solid tumors. Indapta Therapeutics Inc. is...
BioCentury | Sep 2, 2020
Management Tracks

Namouni to lead Blueprint R&D; plus Davar to head R&D at Acadia, Napolitano replaces Burow on Vir’s board, and more

...said it has started its first clinical trial, a Phase I study of cough candidate NOC-100.Indapta Therapeutics Inc....
...policy research organization’s CSO and EVP for the past 10 years. BC Staff Acadia Pharmaceuticals Inc. Nocion Therapeutics Inc. Indapta Therapeutics Inc. Blueprint...
BioCentury | Mar 14, 2020
Emerging Company Profile

Indapta harnesses natural NK cell subset to create allogeneic cancer therapy

...number of cancer patients it could treat relative to genetically edited allogeneic NK cell therapies. Indapta Therapeutics Inc....
...with undisclosed companies regarding partnerships that pair its G-NK cells with existing mAbs. COMPANY PROFILE Indapta Therapeutics Inc....
Items per page:
1 - 4 of 4